pleckstrin homology and RhoGEF domain containing G6Genealiases: ARHGEF46 · MyoGEF
Q-omics provides the consensus-scored PLEKHG6 profile across patient tissues and cancer cell-line models. PLEKHG6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLEKHG6 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PLEKHG6 RNA expression shows 17,535 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where PLEKHG6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHG6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHG6 survival associations across molecular data types. PLEKHG6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHG6 RNA expression–survival associations across cancer types. High PLEKHG6 expression shows unfavorable associations in UVM, LGG, THCA and TGCT, but favorable associations in ACC and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PLEKHG6 RNA expression.
This table summarizes PLEKHG6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHG6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHG6 shows lower tumor expression in COAD, KICH and HNSC and higher tumor expression in LUAD, LUSC and UCEC. The COAD box plot shows higher PLEKHG6 RNA expression in normal versus tumor tissue (log2 FC = −0.901, t-test p < 0.001).
This table shows molecular features associated with PLEKHG6 in patient tissues and cancer cell lines. In patient samples, PLEKHG6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHG6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_NSCLC_LUAD.
